HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CNTX-4975

high‐purity synthetic trans‐capsaicin

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Burges, Robin: 1 article (01/2019)
2.	Campbell, James N: 1 article (01/2019)
3.	Ervin, John: 1 article (01/2019)
4.	Guedes, Kimberly: 1 article (01/2019)
5.	Hanson, Peter D: 1 article (01/2019)
6.	Nezzer, Jennifer: 1 article (01/2019)
7.	Nieves, Yeni: 1 article (01/2019)
8.	Stevens, Randall M: 1 article (01/2019)

Related Diseases

1.	Pain (Aches) 01/01/2019 - "CNTX-4975 1.0 mg produced a significant decrease in OA knee pain through 24 weeks; CNTX-4975 0.5 mg significantly improved pain at 12 weeks, but the effect was not evident at 24 weeks." 01/01/2019 - "In this study, CNTX-4975 provided dose-dependent improvement in knee OA-associated pain. " 01/01/2019 - "At week 12, greater decreases in the AUC for the pain score were observed with CNTX-4975 in the 0.5 mg and 1.0 mg groups versus placebo (0.5 mg group least squares mean difference [LSMD] -0.79, P = 0.0740; 1.0 mg group LSMD -1.6, P < 0.0001). " 01/01/2019 - "In this phase II multicenter double-blind study, patients ages 45-80 years who had stable knee OA were randomized in a 2:1:2 ratio to receive a single intraarticular injection of placebo, CNTX-4975 0.5 mg, or CNTX-4975 1.0 mg. The primary efficacy end point was area under the curve (AUC) for change from baseline in daily Western Ontario and McMaster Universities Osteoarthritis Index pain with walking score (range 0-10, 0 = none and 10 = extreme) through week 12. "
2.	Osteoarthritis 01/01/2019 - "In this phase II multicenter double-blind study, patients ages 45-80 years who had stable knee OA were randomized in a 2:1:2 ratio to receive a single intraarticular injection of placebo, CNTX-4975 0.5 mg, or CNTX-4975 1.0 mg. The primary efficacy end point was area under the curve (AUC) for change from baseline in daily Western Ontario and McMaster Universities Osteoarthritis Index pain with walking score (range 0-10, 0 = none and 10 = extreme) through week 12. "

Related Therapies and Procedures

1.	Intra-Articular Injections